|
|
|
|
|
|
|
30.03.26 - 15:02
|
XFRA: 2KZ0: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
KEZAR LIFE SC.NEW DL-,001 2KZ0 US49372L2097
AB/FROM ONWARDS 30.03.2026 14:47 CET...
|
|
|
30.03.26 - 14:18
|
XFRA: 2KZ0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
KEZAR LIFE SC.NEW DL-,001 2KZ0 US49372L2097 BAW/UFN...
|
|
|
|
|
30.03.26 - 14:06
|
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right (Business Wire)
|
|
|
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the “Merger Agreement”) to acquire Kezar Life Sciences, Inc. (NASDAQ: KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proceeds relating to Kezar's collaboration with Everest Medicines and Kezar's sale of its Sec61‑based discovery and development program to Enodia Therapeutics; and (iii) 100% of Kezar's closing net cash in excess of $50...
|
|
|
|
|
|
|
17.10.25 - 21:30
|
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans (Benzinga)
|
|
|
Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest.
Latest Ratings for KZR
DateFirmActionFromTo Dec 2021Wells FargoInitiates Coverage OnOverweight Nov 2021HC Wainwright & Co.MaintainsBuy Jul 2021JonesTradingInitiates Coverage OnBuy
View More Analyst Ratings for KZR
View the Latest Analyst Ratings
read more...
|
|
|
17.10.25 - 11:30
|
Kezar Life Sciences +51%: NBC-Spekulation geht auf! (Sharedeals)
|
|
|
Wieder ein Fall von: Mission erfolgreich! Die Aktie von Kezar Life Sciences stand im No Brainer Club die letzten Monate auf der Kaufliste. Gestern nachbörslich kam es zur Kursexplosion. Kezar Life Sciences hat ein wichtiges Update zu seinem Wirkstoffkandidaten Zetomipzomib bekanntgegeben. Demnach verlangt die US-Arzneimittelbehörde FDA vor weiteren Studien zur Autoimmunhepatitis zunächst zusätzliche Tests zur […]
The post Kezar Life Sciences +51%: NBC-Spekulation geht auf! first appeared on sharedeals.de....
|
|
|
|
|
|
|
13.08.25 - 22:03
|
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis
Submitted Type C meeting request to the FDA to meet during the fourth quarter of 2025 to discuss the development plan for zetomipzomib in autoimmune hepatitis
PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting® 2025
Cash, cash equivalents and marketable securities totaled $101 million as of June 30, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
“We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis,” said Chris Kirk, PhD, CEO and co-founder of Kezar. “We are committed to workin...
|
|
|
|
|
|
|
|
|
|
|
13.05.25 - 22:03
|
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
Reported positive topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH)
Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
“We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founder of Kezar. “There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies. We are encouraged by the promising safety and efficacy data in this difficult-to-treat patien...
|
|
|
25.03.25 - 12:36
|
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results (Business Wire)
|
|
|
Company-hosted conference call and webcast to be held today at 8:00 a.m. ET
Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population.
In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients.
In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared to 1 of 8 placebo patients.
Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks (including the ongoing open-label extension), and no disease flares were reported in any zetomipzomib-treated patient achieving CR during study.
Favorable safety profile was observed during the 6-month, blinded tre...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
